Mezzion Pharmaceuticals

Executive Summary

Mezzion Pharmaceuticals is a private biopharmaceutical company dedicated to developing therapies for patients with Fontan circulation, a rare and complex congenital heart defect. Its lead asset, udenafil, is a phosphodiesterase-5 (PDE5) inhibitor currently in late-stage development for adolescents with Fontan physiology. The company aims to address the significant unmet need for long-term management of this patient population, which currently lacks approved pharmacological options. Udenafil has shown promise in improving exercise capacity and hemodynamics in earlier studies, positioning it as a potential first-in-class therapy. With a focused pipeline, Mezzion is approaching key regulatory milestones that could unlock significant value for patients and stakeholders. The company’s strategy centers on advancing udenafil through the FDA approval process, driven by strong clinical data and advocacy from the congenital heart disease community.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Trial Top-Line Results60% success
• H1 2027New Drug Application (NDA) Submission50% success
• TBDStrategic Partnership or Licensing Deal40% success